| ￥3000 | |
| Z05862-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 36.74 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of TAFA2/FAM19A2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
TAFA2/FAM19A2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Tafa is a family of small secreted proteins with conserved cysteine residues and restricted expression in the brain. It is composed of five highly homologous genes referred to as Tafa-1 to -5. FAM19A2/TAFA-2 induces skeletal stem cell migration through the activation of Rac1-p38 signaling and is highly abundant in the central nervous system and MIP1α regulates energy balance. |
| Synonyms | TAFA2; FAM19A2; TAFA-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
